2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4056 High plasma cell proliferative fraction identifies patients with inferior outcomes after ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Saurabh Zanwar, MBBS, MD, Yi Lin Jr, MD, PhD2, Sikander Ailawadhi, MD3, Nadine Abdallah I, MD4, P. Leif Bergsagel, MD5, Moritz Binder, MD, MPH6, Saurabh Chhabra, MD, MBBS7, Joselle M Cook, M.D.8, Andre De Menezes Silva Corraes, MD9, Morie Gertz10, Wilson Gonsalves, MD11, Susan Geyer, PhD12, Dragan Jevremovic, MD PhD13, Taxiarchis Kourelis, MD14, Nelson Leung, MD15, Kenneth Lim16, Gregory Otteson17, Ricardo Daniel Parrondo, MD18, Christoph Schaefers, MD19, Jansen N Seheult, MBBCh, BAO, MSc, MS, MD20, Melinda Tan, MD21, Rahma Warsame, MD22, Udit Yadav, MBBS23, J Erin Wiedmeier-Nutor, MD,MPH24, S. Vincent Rajkumar, MD25, Rafael Fonseca, MD26, Prashant Kapoor, MD27, Shaji Kumar, MD28
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Jacksonville, Florida, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Scottsdale, Arizona, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Jacksonville, Florida, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Scottsdale, Arizona, United States
24 Mayo Clinic, Scottsdale, Arizona, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Scottsdale, Arizona, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 Mayo Clinic, Rochester, Minnesota, United States

Background: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy that produces high response rates and durable progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). However, clinical outcomes remain heterogeneous. The proliferative fraction of monotypic/clonal plasma cells (CPCs), measured by the proportion of cells in S-phase, is an established independent prognostic marker in newly diagnosed multiple myeloma as well as following autologous stem cell transplantation. We evaluated the association between plasma cell proliferative fraction and outcomes after cilta-cel therapy.

Methods: Patients with RRMM who received cilta-cel between February 2022 and November 2024 were included. Plasma cell proliferative fraction was assessed on pre-lymphodepletion bone marrow aspirates using validated multiparametric flow cytometry methods. Patients with an S-phase fraction ≥2% were classified as having a proliferative phenotype (PRHigh) based on previously established thresholds, whereas those with an S-phase fraction <2% were classified as PRLow. Progression-free survival (PFS) was measured from cilta-cel infusion to  progression of MM or death. High-risk cytogenetic abnormalities (HRCA) were defined using an adapted IMS/IMWG consensus definition [TP53 mutation and biallelic del(1p) status were unavailable].

Results: We evaluated 232 patients treated with cilta-cel in the study period, with median follow-up was 17 months (95% CI, 16.3–18.4). Median age at infusion was 65 years (range, 31–86), 46% were female, and patients had received a median of four prior lines of therapy (range, 1–14). S-phase was assessed in 198 patients (85.3%). PFS did not differ between patients with and without S-phase testing (p=0.10).

Among the 198 patients assessed, 76 (38.4%) had unmeasurable S-phase (PRunmeasurable), because of low bone marrow CPCs (n=74) or technical artefacts (n=2). Of the remaining 122 patients with reportable S-phase, 77 (59%) had S-phase ≥2% i.e. PRHigh, including 24 (19.7%) with S-phase ≥5%. Patients with PRHigh had an increased prevalence of HRCAs (57% vs. 24%, p<0.01) shorter time from diagnosis of MM to CAR-T infusion (74 months vs. 91 months, p=0.02), higher degree of bone marrow plasma cell (BMPC≥50%, 30% vs. 16%, p<0.01) infiltrate, higher rates of extramedullary disease (EMD; 13% vs. 2%, p<0.01) and elevated (≥400 ng/mL) ferritin levels (36% vs. 11%,p<0.01), compared to the PRLow cohort. Median prior lines of therapies (4 in each cohort, p=0.7), proportion of triple-class refractory (75% vs. 69%, p=0.7) and penta-refractory (29 vs. 22%, p=0.7) patients was comparable between the PRHigh  and PRLow cohorts.

At 3 months, the PRHigh cohort demonstrated lower rates of deeper resposes (≥very good partial response) compared to the PRLow cohort and PRunmeasurable(63% vs. 81% vs. 83% respectively; p<0.01).The 18-month PFS rate was 87% for patients with PRLow, 72.1% for those with PRunmeasurable, and 48.9% for those with PRHigh (p<0.0001). Corresponding 18-month overall survival rates were 92.8%, 78.9%, and 76%, respectively (p = 0.02). Among the subset of patients with S-phase ≥5%, the 18-month PFS rate was 27% [median PFS 10.6 months (95% CI: 4.8-14.8)].

Among patients with reportable S-phase (n = 121), multivariable Cox analysis adjusting for prior BCMA-directed therapy, IMS/IMWG HRCA, penta-drug refractoriness, EMD, high BMPC (≥50%) and ferritin ≥400 ng/mL, demonstrated that PRHigh remained independently associated with inferior PFS (HR 3.7, 95% CI 1.5–9.1, p=0.005). In a second multivariable model including patients with unmeasurable S-phase (n = 190), PRHigh remained independently associated with inferior PFS (HR 3.4, 95% CI 1.4–7.9,p=0.005) compared to PRLow, whereas patients with PRunmeasurable had outcomes comparable to those with PRLow (HR 1.6, 95% CI 0.6–4.1,  p=0.17).

Conclusion: In this uniformly treated cohort of patients with RRMM receiving cilta-cel, an elevated plasma cell proliferative fraction was independently associated with inferior PFS. S-phase assessment identifies a subgroup at particularly high risk of early relapse despite CAR-T therapy and may provide a practical biomarker for future risk-adapted consolidation or maintenance strategies.

Saurabh Zanwar, MBBS, MD: International Waldenstrom Macroglobulinemia Foundation - Research Funding; International Myeloma Society - Research Funding